藥明康德(603259.SH)2019年度淨利潤降17.96%至18.55億元 擬10轉4派3.37元
格隆匯3月24日丨藥明康德(603259.SH)發佈2019年年度報告,實現營業收入128.72億元,同比增長33.89%;歸屬於上市公司股東的淨利潤18.55億元,同比下降17.96%;歸屬於上市公司股東的扣除非經常性損益的淨利潤19.14億元,同比增長22.82%;基本每股收益1.14元,擬每10股派發現金紅利3.37元(含税),同時以資本公積轉增股本,每10股轉增4股。經營活動產生的現金流量淨額29.16億元,同比增長77.76%。
公司屬於醫藥研發服務行業,通過自身的研發和生產平台,為客户賦能,助力客户更快更好的進行新藥研發。公司主營業務涵蓋CRO、化學藥物CDMO/CMO、細胞和基因治療CDMO/CMO等領域。報告期內,公司通過全球29個研發基地和分支機構,為超過3900家全球和中國客户提供服務。
營業收入增長,主要系本年內各個業務板塊均保持強勁的發展勢頭,中國區和美國區實驗室服務,CDMO/ CMO服務,臨牀研究及其他CRO服務業務均增速明顯。
歸屬於上市股東的淨利潤同比下降17.96%,主要系公司所投資標的公允價值變動損失1.80億元,較上年同期公允價值變動收益人民幣6.16億元大幅減少7.96億元所致。扣除所投資標的公允價值變動影響後,報告期歸屬於上市公司股東的淨利潤較上年同期增長23.70%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.